Aegerion Pharmaceuticals — Merger or Acquisition (August 2016)
9 slides from Aegerion Pharmaceuticals's merger presentation, Aug 10, 2016
Slide 1: Forward-Looking Statements
Forward-Looking Statements This press release contains forward-looking statements, including statements regarding: our expectations about JUXTAPID’s market opportunity; MYALEPT sales; the proposed transaction between QLT and Aegerion, the timing and financial and strategic benefits thereof, the expe
Slide 2: Important Information for Investors and Shareholders
Important Information for Investors and Shareholders Additional Information about the Proposed Transaction and Where to Find It This communication does not constitute an offer to buy or solicitation of any offer to sell securities or a solicitation of any vote or approval. It does not constitute a p
Slide 3: Aegerion's Roadmap: Steps to Value Creation and Future Growth
Aegerion’s Roadmap Steps to Value Creation and Future Growth REPAIR immediate issues REALIGN cost structure Enhance PIPELINE Leverage Aegerion’s capabilities for TRANSFORMATIVE IMPACT
Slide 4: Novelion: A Strong, Global, Rare-Disease Focused Organization
Novelion: A Strong, Global, Rare-Disease Focused Organization Steps to Value Creation and Future Growth Global infrastructure Local patient solutions Field force with experience establishing products in the marketplace Deep market knowledge Proven innovation Two commercial programs (Aegerion) and on
Slide 5: Maximizing JUXTAPID Franchise
Maximizing JUXTAPID Franchise U.S. Ended 2Q16 with 423 patients on therapy globally: Ended 2Q16 with 296 U.S. patients Continue to see erosion of JUXTAPID patients at a meaningful rate, due to the availability of PCSK9 inhibitors Expect continued role for JUXTAPID as a treatment for adult HoFH due t
Slide 6: MYALEPT Gaining Traction Internationally
MYALEPT Gaining Traction Internationally U.S. Ended 2Q16 with 116 patients on therapy globally: Ended 2Q16 with 94 U.S. patients GL patient identification and prescription generation on track; positive feedback from physicians and patients regarding treatment benefit Continue to experience long paye
Slide 7: Second Quarter 2016 Financial Results Summary
Second Quarter 2016 Financial Results Summary Q2 2016 Net Loss: GAAP: $(46.8)M, $(1.59) per share Non-GAAP*: $(21.4)M, $(0.72) per basic share Cash and cash equivalents: $46.1M at June 30, 2016 $64.5M at December 31, 2015 Reiterated Financial Guidance: Total full-year 2016 global net product sales:
Slide 8: Second Quarter 2016 Financial Results Summary
Second Quarter 2016 Financial Results Summary Total Net Product Sales Q2 2016 Net Loss: 70 $042 = GAAP: $(46.8)M, $(1.59) per share 60 * Non-GAAP": — $(21.4)M, $(0.72) per basic share 50 sas A “0 re Cash and cash equivalents: 5 a + $46.1M at June 30, 2016 oo ‘© $64.5M at December 31, 2015 ss03 . Rei
Slide 9: Aegerion
Aegerion’ svn Cont © 096 Amnon Ps
Aegerion Pharmaceuticals — Merger or Acquisition (August 2016) on 6ix